Editorial
doi: 10.7326/M19-0141.
Epub 2019 Feb 19.
Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine
Affiliations
- PMID: 30776802
- DOI: 10.7326/M19-0141
Item in Clipboard
Editorial
Prevention of Shingles: Better Protection and Better Value With Recombinant Vaccine
Ann Intern Med.
.
No abstract available
Comment on
-
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.Ann Intern Med. 2019 Mar 19;170(6):380-388. doi: 10.7326/M18-2347. Epub 2019 Feb 19. Ann Intern Med. 2019. PMID: 30776797
Similar articles
-
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Ann Intern Med. 2006 Sep 5;145(5):317-25. doi: 10.7326/0003-4819-145-5-200609050-00004. Ann Intern Med. 2006. PMID: 16954357
-
Q: Who should receive the shingles vaccine?Cleve Clin J Med. 2009 Jan;76(1):45-8. doi: 10.3949/ccjm.75a.08046. Cleve Clin J Med. 2009. PMID: 19122110 No abstract available.
-
[The clinical and epidemic characteristics of shingles (herpes zoster) and its prevention with vaccines].Ter Arkh. 2013;85(11):130-3. Ter Arkh. 2013. PMID: 24432613 Review. Russian.
-
Shingrix--an adjuvanted, recombinant herpes zoster vaccine.Med Lett Drugs Ther. 2017 Dec 4;59(1535):195-196. Med Lett Drugs Ther. 2017. PMID: 29186082 No abstract available.
-
[Vaccines against Herpes zoster: Effectiveness, safety, and cost/benefit ratio].Presse Med. 2016 Feb;45(2):162-76. doi: 10.1016/j.lpm.2015.10.015. Epub 2015 Dec 24. Presse Med. 2016. PMID: 26724874 Review. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
